Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Eine Phase-1-Studie von PRT12396 bei Teilnehmern mit ausgewählten myeloproliferativen Neoplasien

28. Oktober 2026 aktualisiert von: Prelude Therapeutics Incorporated

Eine Phase-1-, offene, multizentrische Studie zur Sicherheit und Wirksamkeit von PRT12396 bei Teilnehmern mit Polycythaemia vera und Myelofibrose

This is a first-in-human, open-label, multi-center Phase 1 study designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF), and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]). The study consists of a dose-escalation phase followed by a dose-expansion phase to further evaluate selected dose level(s).

Studienübersicht

Status

Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This first-in-human, open-label, multi-center Phase 1 study is designed to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in participants with high-risk polycythemia vera (PV) and myelofibrosis (MF). Eligible MF populations include participants with intermediate-1, intermediate-2, or high-risk primary MF, as well as post-polycythemia vera MF or post-essential thrombocythemia MF, with evidence of disease burden based on splenomegaly.

The study is conducted in two parts:

Part 1 (dose escalation) evaluates escalating oral doses of PRT12396 to evaluate safety and tolerability and to determine the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]).

Part 2 (dose expansion) enrolls additional participants at selected dose level(s) to further characterize the safety, tolerability, pharmacokinetics, and preliminary efficacy of PRT12396 in the PV and MF populations.

Approximately up to 100 participants are planned for enrollment across both parts of the study.

Studientyp

Interventionell

Einschreibung (Geschätzt)

100

Phase

  • Phase 1

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studienorte

    • South Australia
      • Adelaide, South Australia, Australien, 5000
        • Rekrutierung
        • Royal Adelaide Hospital
    • Victoria
      • Clayton, Victoria, Australien, 3168
        • Rekrutierung
        • Monash Health, Monash Medical Centre
    • Western Australia
      • Nedlands, Western Australia, Australien, 6009
        • Rekrutierung
        • One Clinical Research
      • Nice, Frankreich, 06200
        • Rekrutierung
        • Nice University Medicâl Center (CHU Nice, Hôpital Archet 1)
      • Paris, Frankreich, 75010
        • Rekrutierung
        • Saint-Louis Hospital
      • Toulouse, Frankreich, 31059
        • Rekrutierung
        • Oncopole Claudius Regaud
      • Florence, Italien, 50134
        • Rekrutierung
        • Azienda Ospedaliero Universitaria Careggi
      • Barcelona, Spanien, 08036
        • Rekrutierung
        • Hospital Clinic de Barcelona
      • Madrid, Spanien, 28034
        • Rekrutierung
        • Hospital Universitario Ramon y Cajal
      • Madrid, Spanien, 28041
        • Rekrutierung
        • Hospital Universitario 12 de Octubre
      • Valencia, Spanien, 46010
        • Rekrutierung
        • Hospital Clínico Universitario de Valencia
    • California
      • Los Angeles, California, Vereinigte Staaten, 90095
        • Rekrutierung
        • UCLA Ronald Reagan Medical Center
      • Sacramento, California, Vereinigte Staaten, 95817
        • Rekrutierung
        • University of California, Davis Comprehensive Cancer Center
    • Colorado
      • Denver, Colorado, Vereinigte Staaten, 80218
        • Rekrutierung
        • Colorado Blood Cancer Institute
    • Florida
      • Coral Springs, Florida, Vereinigte Staaten, 33065
        • Rekrutierung
        • BRCR Global - Coral Springs
      • Miami, Florida, Vereinigte Staaten, 33136
        • Rekrutierung
        • Sylvester Comprehensive Cancer Center
      • Tampa, Florida, Vereinigte Staaten, 33612
        • Rekrutierung
        • Moffitt Cancer Center
    • Michigan
      • Grand Rapids, Michigan, Vereinigte Staaten, 49546
        • Rekrutierung
        • START Midwest, LLC
    • Pennsylvania
      • Philadelphia, Pennsylvania, Vereinigte Staaten, 19107
        • Rekrutierung
        • Thomas Jefferson University, Sidney Kimmel Cancer Center, Clinical Trials Office
    • Tennessee
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Rekrutierung
        • Tristar BMT
      • Nashville, Tennessee, Vereinigte Staaten, 37203
        • Rekrutierung
        • Tennessee Oncology, PLLC - Investigational Drug Services
    • Texas
      • Houston, Texas, Vereinigte Staaten, 77030
        • Rekrutierung
        • The University of Texas, MD Anderson Cancer Center

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

18 Jahre und älter (Erwachsene, Älterer Erwachsener)

Akzeptiert gesunde Freiwillige

Nein

Studienberechtigte Geschlechter

Alle

Beschreibung

Inclusion Criteria:

  • Willing and able to comply with all scheduled visits, treatment plan, laboratory tests, lifestyle considerations (including contraception requirements), and other study procedures.
  • Confirmed diagnosis of PV or MF according to WHO 2016 or revised ICC/WHO 2022 criteria
  • Documented presence of a JAK2 V617 mutation
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0-1
  • Estimate life expectancy of ≥12 weeks per investigator assessment.
  • Negative serum or urine pregnancy test and agree to use contraception or maintain true abstinence.
  • Adequate organ function and bone marrow reserves (hematology, renal, and hepatic)

Exclusion Criteria:

  • History of another malignancy within 3 years prior to enrollment, except for malignancy considered cured with low risk of recurrence.
  • Clinically significant anemia due to nutritional deficiency or hemolytic disorders.
  • Active or uncontrolled infection requiring systemic therapy or hospitalization.
  • Any other medical or psychiatric conditions that, in the Investigator's judgment, would increase risk or interfere with study participation or interpretation of results.
  • Clinically significant or uncontrolled medical conditions, including active infection or cardiovascular disease, that would increase risk or interfere with study participation.
  • Unresolved toxicity Grade >1 from prior anticancer therapy, except for alopecia or peripheral neuropathy Grade ≤2.
  • Pregnancy or breastfeeding
  • Known sensitivity or contraindication to any component of study, or the excipients of study treatment.
  • Prior systemic therapy for PV or MF, prior or planned allogeneic hematopoietic stem-cell transplantation, recent major surgery, prior splenectomy or prior splenic irradiation, or use of hematopoietic growth factors within protocol-defined washout periods.
  • Use of strong or moderate cytochrome P450 (CYP) 3A4 inhibitor or inducer, sensitive CYP3A substrates with narrow therapeutic range, or acid-reducing agents that cannot be discontinued prior to study treatment.
  • Participation in another interventional clinical study.

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Nicht randomisiert
  • Interventionsmodell: Sequenzielle Zuweisung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Experimental: PRT12396: MF

Participants with myelofibrosis receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

Experimental: PRT12396: PV

Participants with polycythemia vera receive PRT12396, an investigational oral capsule, administered twice daily. The study includes a dose-escalation followed by dose-expansion at the recommended dose for expansion (RDE)

PRT12396 is an investigational oral capsule administered twice daily at the assigned dose level or RDE. Capsules are swallowed whole with water and may be taken one hour before or two hours after meals.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Dose limiting toxicity (DLT) of PRT12396
Zeitfenster: Through cycle 1 (4 weeks)

Incidence of dose limiting toxicities, defined according to protocol-specified criteria

Through cycle 1 (4 weeks)
Incidence and severity of Adverse events
Zeitfenster: Through study completion, an average of 2 years

Incidence and severity of treatment-emergent adverse events (AEs), graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE), Version 6.0

Through study completion, an average of 2 years
Adverse Events Leading to Dose Modifications or Discontinuation
Zeitfenster: Through study completion, an average of 2 years

Incidence of AEs leading to dose reductions, dose interruptions, treatment discontinuations, and clinically significant laboratory abnormalities

Through study completion, an average of 2 years
Maximum tolerated dose (MTD) and Recommended Dose(s) for Expansion (RDE[s]) of PRT12396
Zeitfenster: Through study completion, an average of 2 years

Determination of the maximum tolerated dose (MTD) and recommended dose(s) for expansion (RDE[s]) based on evaluation of DLTs, safety, and tolerability data

Through study completion, an average of 2 years

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Hematologic Response Rate (PV)
Zeitfenster: Through study completion, an average of 2 years

Proportion of participants with polycythemia vera (PV) achieving best overall hematologic response (complete hematologic response or partial hematologic response) from the overall response assessments by Investigator

Through study completion, an average of 2 years
Duration of Hematologic Response (PV)
Zeitfenster: Through study completion, an average of 2 years

Duration of hematologic response in PV participants, defined as the time from first documented response (best overall hematologic response) to disease progression or death, whichever comes first

Through study completion, an average of 2 years
Hematocrit Control Without Phlebotomy Requirements (PV)
Zeitfenster: Through study completion, an average of 2 years

Proportion of PV participants achieving and maintaining hematocrit control without phlebotomy, time to first phlebotomy, and frequency of phlebotomy

Through study completion, an average of 2 years
Spleen Response (MF)
Zeitfenster: Through study completion, an average of 2 years

Assessment of spleen response including proportion achieving protocol-specified reduction in spleen volume, time to spleen response, duration of spleen response, and reduction in palpable spleen length

Through study completion, an average of 2 years
Change from Baseline in Hemoglobin (MF)
Zeitfenster: Through study completion, an average of 2 years

Change from baseline in hemoglobin levels in MF participants

Through study completion, an average of 2 years
Change from Baseline in Platelet Count (MF)
Zeitfenster: Through study completion, an average of 2 years

Change from baseline in platelet count in MF participants

Through study completion, an average of 2 years
Change from Baseline in Absolute Neutrophil Count (MF)
Zeitfenster: Through study completion, an average of 2 years

Change from baseline in absolute neutrophil count in MF participants

Through study completion, an average of 2 years
Transfusion Independence (MF)
Zeitfenster: Through study completion, an average of 2 years

Proportion achieving transfusion independence and duration of transfusion independence as defined by protocol criteria

Through study completion, an average of 2 years
Maximum Observed Plasma Concentration (Cmax)
Zeitfenster: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Maximum observed plasma concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Time To Maximum Concentration (Tmax)
Zeitfenster: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Time to maximum concentration will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Area under the plasma concentration versus time curve (AUC)
Zeitfenster: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Area under the plasma concentration-time curve will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Terminal Elimination Half-life (T1/2)
Zeitfenster: Cycle 1 Day 1

Terminal elimination half-life will be calculated using non-compartmental analysis

Cycle 1 Day 1
Steady State Trough Concentrations
Zeitfenster: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Steady state trough concentrations will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Clearance
Zeitfenster: Cycle 1 Day 1

Clearance will be calculated using non-compartmental analysis

Cycle 1 Day 1
Accumulation
Zeitfenster: Up to Cycle 4 Day 1 (each cycle is 4 weeks)

Accumulation will be calculated using non-compartmental analysis

Up to Cycle 4 Day 1 (each cycle is 4 weeks)
Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS)
Zeitfenster: Through study completion, an average of 2 years

Patient-reported outcomes assessed using the Myeloproliferative Neoplasm Symptom Assessment Form Total Symptom Score (MPN-SAF TSS), evaluated as change from baseline at protocol-specified time points. The MPN SAF TSS is a validated questionnaire in which individual symptoms are scored using a numeric rating scale ranging from 0 to 10, with 0 indicating no symptoms and 10 indicating the worst imaginable symptoms; higher scores indicate greater symptom severity.

Through study completion, an average of 2 years
Patient Global Impression of Change (PGI-C)
Zeitfenster: Through study completion, an average of 2 years

Participant reported outcomes assessed using the Patient Global Impression of Change (PGI-C), evaluated at protocol-specified time points. The PGI C is a global assessment scale in which participants rate their overall change in condition since baseline using a 7 point ordinal scale ranging from "very much improved" to "very much worse," with lower scores indicating improvement and higher scores indicating worsening of symptoms.

Through study completion, an average of 2 years

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

29. April 2026

Primärer Abschluss (Geschätzt)

1. April 2028

Studienabschluss (Geschätzt)

1. April 2028

Studienanmeldedaten

Zuerst eingereicht

26. Februar 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

9. März 2026

Zuerst gepostet (Tatsächlich)

13. März 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

29. Oktober 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

28. Oktober 2026

Zuletzt verifiziert

1. September 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Andere Studien-ID-Nummern

  • PRT12396-01
  • 2026-525484-40-00 (Ctis)

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Ja

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .